A Phase IB (Repeat Dosing) Trial of Second Dose Oncolytic HSV Administered Intratumorally in Patients With Recurrent Malignant Glioma.
Latest Information Update: 03 Feb 2025
At a glance
- Drugs C 134 (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Gliosarcoma
- Focus Adverse reactions
Most Recent Events
- 29 Jan 2025 Status changed from not yet recruiting to recruiting.
- 18 Jan 2024 Planned initiation date changed from 1 Jan 2024 to 1 Aug 2025.
- 18 Jan 2024 New trial record